-

Tempus to Participate in Morgan Stanley’s 23rd Annual Global Healthcare Conference

CHICAGO--(BUSINESS WIRE)--Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine and patient care, will participate in Morgan Stanley’s 23rd Annual Global Healthcare Conference. The conference will take place September 8-10 in New York City. Eric Lefkofsky, Founder and CEO of Tempus, and Jim Rogers, Chief Financial Officer, will participate in a fireside chat on September 8 from 1:05 to 1:40 p.m. EST.

A live audio webcast of the conversation will be available here.

About Tempus

Tempus is a technology company advancing precision medicine through the practical application of artificial intelligence in healthcare. With one of the world’s largest libraries of multimodal data, and an operating system to make that data accessible and useful, Tempus provides AI-enabled precision medicine solutions to physicians to deliver personalized patient care and in parallel facilitates discovery, development and delivery of optimal therapeutics. The goal is for each patient to benefit from the treatment of others who came before by providing physicians with tools that learn as the company gathers more data. For more information, visit tempus.com.

Contacts

Hanah Heintzelman
hanah.heintzelman@tempus.com

Tempus AI, Inc.

NASDAQ:TEM

Release Versions

Contacts

Hanah Heintzelman
hanah.heintzelman@tempus.com

More News From Tempus AI, Inc.

Tempus and Predicta Biosciences Announce Collaboration to Expand Life Sciences Access to Ultrasensitive Whole-Genome Sequencing Assay for Hematologic Malignancies and MRD Monitoring

CHICAGO--(BUSINESS WIRE)--Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine, and Predicta Biosciences, a precision oncology company developing novel diagnostic solutions for deep molecular characterization of hematologic malignancies with a focus on circulating tumor cells, today announced the commercial expansion of a co-branded whole-genome sequencing (WGS) assay, currently known as GenoPredicta™, intended for the comprehensive genomi...

Tempus Announces 31 Abstracts for Presentation at the American Association for Cancer Research Annual Meeting 2026

CHICAGO--(BUSINESS WIRE)--Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine, today announced the acceptance of 31 abstracts—including one oral presentation—for the American Association for Cancer Research (AACR) Annual Meeting 2026 taking place April 17–22 in San Diego. “The research that Tempus is presenting at this year’s AACR annual meeting underscores the scale and real-world impact of Tempus’ multimodal dataset and AI-enabled diagn...

Tempus Launches Automated “Active Follow-Up” Service to Support Guideline-Concordant Care

CHICAGO--(BUSINESS WIRE)--Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine, today announced the launch of an automated clinical update service designed to support guideline-concordant care by placing patients on an "active follow-up" track. This integrated workflow provides clinicians with ongoing therapy monitoring and context-aware notifications seamlessly delivered through Hub, Tempus’ secure, AI-enabled physician portal. Because NC...
Back to Newsroom